EQUILLIUM, INC. Proceeds from Stock Plans
EQUILLIUM, INC. (EQ) reported Proceeds from Stock Plans of $86.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2023-11-08
- EQUILLIUM, INC. proceeds from stock plans for the quarter ending 2023-09-30 was $0.00.
- EQUILLIUM, INC. proceeds from stock plans for the quarter ending 2022-12-31 was $73.00K, a 45.52% decline year-over-year.
- EQUILLIUM, INC. proceeds from stock plans for the quarter ending 2022-09-30 was $0.00.
- EQUILLIUM, INC. proceeds from stock plans for the quarter ending 2021-12-31 was $134.00K, a 123.33% increase year-over-year.
- EQUILLIUM, INC. proceeds from stock plans for fiscal 2022 was $214.00K, a 18.01% decline from fiscal 2021.
- EQUILLIUM, INC. proceeds from stock plans for fiscal 2021 was $261.00K, a 67.31% increase from fiscal 2020.
- EQUILLIUM, INC. proceeds from stock plans for fiscal 2020 was $156.00K, a 271.43% increase from fiscal 2019.
- EQUILLIUM, INC. proceeds from stock plans for fiscal 2019 was $42.00K.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $86.00K 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $86.00K 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | $73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $73.00K derived: sum of 2 quarters · filed 2023-11-08 | $214.00K 10-K · filed 2023-03-23 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $141.00K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $141.00K 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $134.00K derived: sum of 2 quarters · filed 2023-03-23 | $261.00K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $127.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $127.00K 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $60.00K derived: sum of 2 quarters · filed 2022-03-23 | $156.00K 10-K · filed 2022-03-23 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $96.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $96.00K 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $42.00K 10-K · filed 2021-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |